Impact News +++ Li-FT Power Aktie: Jetzt spekulativ einsteigen? (Aktiencheck) +++ LI-FT POWER Aktie +3,37%

10X GENOMICS Aktie

>10X GENOMICS Aktienkurs

11.965 EUR -0.8% (Tradegate)

Ask: 12.095 EUR / 1660 Stück

Bid: 12.03 EUR / 1670 Stück

Tagesumsatz: 423 Stück

Realtime Kurs von 8 bis 22 Uhr!

10X GENOMICS Aktie über LYNX handeln

Intraday

1 Jahr

>10X GENOMICS Performance

1 Woche: +6,0%

1 Monat: -0,3%

3 Monate: +57,5%

6 Monate: +12,3%

1 Jahr: -40,2%

laufendes Jahr: -13,4%

>10X GENOMICS Aktie

Name:

10X GENOMICS DL -,00001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US88025U1097 / A2PPQJ

Symbol/ Ticker:

1KJ (Frankfurt) / TXG (NASDAQ)

Kürzel:

FRA:1KJ, ETR:1KJ, 1KJ:GR, NASDAQ:TXG

Index:

Webseite:

https://www.10xgenomics.c..

Profil:

10x Genomics Inc. is a biotechnology company known..
>Volltext..

Marktkapitalisierung:

1508.08 Mio. EUR

Unternehmenswert:

1200.4 Mio. EUR

Umsatz:

556.46 Mio. EUR

EBITDA:

-94.36 Mio. EUR

Nettogewinn:

-73.05 Mio. EUR

Gewinn je Aktie:

-0.6 EUR

Schulden:

74.9 Mio. EUR

Liquide Mittel:

343.4 Mio. EUR

Operativer Cashflow:

57.81 Mio. EUR

Bargeldquote:

3.99

Umsatzwachstum:

-7.24%

Gewinnwachstum:

67.92%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 539.747 USD.

Suchwörter:

10X GENOMICS, 10XGENOMICS

Letzte Datenerhebung:

27.08.25

>10X GENOMICS Kennzahlen

Aktien/ Unternehmen:

Aktien: 114.41 Mio. St.

Frei handelbar: 96.37%

Leerverk. Aktien: 12.6%

Rückkaufquote: -0.49%

Mitarbeiter: 1306

Umsatz/Mitarb.: 0.4 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 2.16%

Bewertung:

KGV: -

KGV lG: -

KUV: 2.71

KBV: 2.36

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 71.72%

Gewinnmarge: -13.13%

Operative Marge: -23.29%

Managementeffizenz:

Gesamtkaprendite: -8.86%

Eigenkaprendite: -11.3%

>10X GENOMICS Peer Group

Es sind 601 Aktien bekannt.

>10X GENOMICS Chart & Kurs - NASDAQ

>10X GENOMICS News

27.08.25 - 22:09	10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (PR Newswire)
	PLEASANTON, Calif., Aug. 27, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on......

26.08.25 - 23:01	Insiderhandel: Vorstand verkauft Aktien von 10X Genomics im Wert von 103209 USD (Insiderkauf)
	Hindson, Benjamin J. - Vorstand - Tag der Transaktion: 2025-08-22...

26.08.25 - 23:01	Insiderhandel: Chief Executive Officer verkauft Aktien von 10X Genomics im Wert von 128881 USD (Insiderkauf)
	Saxonov, Serge - Vorstand - Tag der Transaktion: 2025-08-22...

26.08.25 - 23:01	Insiderhandel: Chief Financial Officer verkauft Aktien von 10X Genomics im Wert von 307657 USD (Insiderkauf)
	Taich, Adam - Vorstand - Tag der Transaktion: 2025-08-22...

12.08.25 - 17:30	Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface (Zacks)
	Tsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface rank high on efficiency metrics, signaling strong profit potential in volatile markets....

11.08.25 - 15:00	5 Must-Buy Efficient Stocks to Buy Amid Volatile Market Conditions (Zacks)
	Tsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface top an efficiency-driven stock screen....

08.08.25 - 01:45	10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
	Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

08.08.25 - 01:00	10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
	10x Genomics (TXG) delivered earnings and revenue surprises of +180.00% and +24.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

07.08.25 - 22:06	10x Genomics Reports Second Quarter 2025 Financial Results (PR Newswire)
	PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates Revenue was $172.9 million for the second quarter. Excluding $27.3......

06.08.25 - 20:31	10x Genomics (TXG) Upgraded to Buy: Here′s Why (Zacks)
	10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

10.07.25 - 22:06	10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025 (PR Newswire)
	PLEASANTON, Calif., July 10, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the second quarter ended June 30, 2025 after market close on Thursday, August 7, 2025. The company will host a......

29.05.25 - 17:30	Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

28.05.25 - 00:01	Insiderhandel: Vorstand verkauft Aktien von 10X Genomics im Wert von 62120 USD (Insiderkauf)
	Hindson, Benjamin J. - Vorstand - Tag der Transaktion: 2025-05-22...

28.05.25 - 00:01	Insiderhandel: Chief Financial Officer verkauft Aktien von 10X Genomics im Wert von 33562 USD (Insiderkauf)
	Taich, Adam - Vorstand - Tag der Transaktion: 2025-05-22...

28.05.25 - 00:01	Insiderhandel: Chief Executive Officer verkauft Aktien von 10X Genomics im Wert von 77540 USD (Insiderkauf)
	Saxonov, Serge - Vorstand - Tag der Transaktion: 2025-05-22...

23.05.25 - 14:12	Why 10x Genomics Stock Was Sliding This Week (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

21.05.25 - 19:45	10x Genomics (TXG) Upgraded to Buy: Here′s What You Should Know (Zacks)
	10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

14.05.25 - 22:09	10x Genomics Announces Patent Litigation Settlement Agreement with Bruker (PR Newswire)
	PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and......

14.05.25 - 13:54	Bruker and 10x Genomics reach global settlement of patent litigation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 17:30	Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here′s is How to Trade (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Affen sind unsere Verwandten, und wir sollten stolz darauf sein. - Dr. Antal Festetics

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram